Search filters
Filters
Clear All

Phase

  • 182
  • 151
  • 2
  • 188
  • 147
  • 17
  • 372
  • 1194
  • 567
  • 28
  • 43
  • 2
  • 1127
  • 1195
  • 5

Found 1200 All Conditions trials

A listing of All Conditions medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

UPCC 05818: A phase I/II study to evaluate the safety pharmacodynamics and efficacy of atezolizumab in combination with entinostat and bevacizumab in patients with advanced renal cell carcinoma

99 years or below
All genders
Phase 2
The purpose of this study is to identify the best dose of entinostat when combined with bevacizumab and atezolizumab and to find out what side effects are caused by the combination of these drugs in patients with renal cell carcinoma.
Learn More

A Prospective Randomised Trial of Early LV Venting Using Impella CP for Recovery in patients with cardiogenic managed with VA ECMO (REVERSE)

99 years or below
All genders
Veno-arterial (VA) extra-corporeal membrane oxygenation (ECMO) is indicated as a haemodynamic rescue strategy in decompensated acute or chronic heart failure presenting as cardiogenic shock. VA ECMO has a number of effects on the circulation including (i) perfusing end-organs, (ii) ventricular unloading, and (iii) improved coronary perfusion. It is a bridge …
Learn More

A Multicenter Randomized Double-Blind Placebo-Controlled 52-Week Maintenance and an Open-Label Extension Study of the Efficacy and Safety of Risankizumab in Subjects with Ulcerative Colitis Who Responded to Induction Treatment in M16-067 or M16-065

99 years or below
All genders
Phase 3
The study will enroll subjects who have completed Study M16-067 or Study M16-065 and have achieved clinical response, defined as decrease from Baseline of induction study of Adapted Mayo score greater than or equal to 2 points and greater than or equal to 30%, PLUS a decrease in rectal bleeding …
Learn More

Pulmonary Vascular Complications of Liver Disease 3

18 years - 99 years
All genders
The main purpose of this study is to determine if certain genes, hormones, or other factors predict the risk of developing lung vessel disease in patients with liver disease and whether they determine outcome. Patients in need of a liver transplant evaluation or have portopulmonary hypertension or are suspected of …
Learn More

UPCC 28218: A Phase II Study of Nivolumab and Ipilimumab in Mucinous Colorectal and Appendiceal Tumors

99 years or below
All genders
Phase 2
This is a single-arm phase II study of twenty-one subjects with mucinous adenocarcinoma of the colon, rectum, or appendix with prior systemic therapy with a fluoropyrimidine, oxaliplatin, and irinotecan. Treatment will consist of nivolumab every 4 weeks and ipilimumab every 8 weeks until disease progression, unacceptable toxicity, or 2 years …
Learn More

UPCC 09517: Phase II study of Pembrolizumab and Itacitinib (INCB039110) for First Line Treatment of Metastatic Non-Small Cell Lung Cancer Expressing PD-L1

99 years or below
All genders
Phase 2
The main purpose of this study is to examine the efficacy of adding itacitinib (also known as INCB039110) to pembrolizumab in patients with previously untreated metastatic non-small cell lung cancer.
Learn More

UPCC 09618: Neoadjuvant PD-1 Blockade in Patients with Stage IIB/C Melanoma

99 years or below
All genders
Phase 2
The main purpose of this study is to determine the rate of positive sentinel lymph nodes (i.e. the closest draining lymph node(s) to the primary melanoma site) and to test whether treatment with pembrolizumab before surgery to remove melanoma reduces the rate of positive sentinel lymph nodes in patients with …
Learn More

UPCC 30818: A Phase 2 Open-Label Single-Arm Multicenter Study to Assess the Safety and Efficacy of ASP1650 a Monoclonal Antibody Targeting Claudin 6 (CLDN6) in Male Subjects with Incurable Platinum Refractory Germ Cell Tumors

99 years or below
All genders
Phase 2
The goal of this study is to confirm that an investigational study drug, ASP1650, is both safe and effective as a treatment in participants with incurable, refractory germ cell tumors that have Claudin 6 (CLDN6) expression.
Learn More

A Pilot Study of Risk-Guided Cardioprotection with Carvedilol in Breast Cancer Patients Treated with Doxorubicin and/or Trastuzumab

99 years or below
All genders
Phase 1
Subjects with breast cancer starting treatment with anthracyclines/trastuzumab will be enrolled and their risk of cardiotoxicity calculated. If elevated risk, they will be randomized to intervention with carvedilol for 1 year vs usual care. Low risk subjects will be usual care. All subjects will be followed with serial echo, survey, …
Learn More

A Phase 2 Multicenter Open-Label Extension Study to Evaluate the Safety and Tolerability of AK002 in Patients with Eosinophilic Gastritis and/or Eosinophilic Gastroenteritis

99 years or below
All genders
Phase 2
AK002 is a humanized non-fucosylated immunoglobulin G1 (IgG1) monoclonal antibody to the inhibitory receptor Siglec-8, present on mast cells, eosinophils, and basophils. Binding of AK002 to Siglec-8 induces a signal that inhibits mast cell activation and can lead to apoptosis in eosinophils. In the presence of effector cells (such as …
Learn More
201 - 210 of 1200